Blood cancer news is in which it is related to all aspects of lymphoma, leukemia. Lymphoma news may include detection, diagnosis, epidemiology, pathology, staging, prognosis, treatment and prevention of lymphoma, such as drugs, genetics, biomarkers, and the integration of different strategies. All types of lymphoma and related subjects are included; both Hodgkinâs and non-Hodgkinâs, including T- and B- Cell, natural killer cell and other lymphomas.
It includes multiple ongoing clinical trials for new anti-EGFR MAbâs, such as panitumumab and matuzumab, and new irreversible TKIâs such as dacomitinib. The purpose of these clinical trials is to demonstrate improved efficacy and safety, in comparison to the therapies already in the market. Additionally, clinical trials are also being conducted to investigate the efficacy of previously approved drugs, such as erlotinib and gefitinib, in combination with other drugs, radiation therapy and adjuvants in an attempt to overcome the secondary EGFR mutation resistance and achieve increased efficacy.
Since targeting multiple pathways is more effective in preventing drug resistance and reducing tumorigenicity, current clinical studies also include drugs that target multiple signalling pathways, such as ZD6474 (vandetanib), which inhibits EGFR and VEGFR activity, and BMS-690514, which is an inhibitor of EGFR, HER-2 and VEGFR. In a study of 60 patients with NSCLC, BMS-690514 administration resulted in disease control in 39% of erlotnib naÃ¯ve patients and 22% of erlotinib failures.
Last date updated on June, 2021